{{'Search' | translate}}
 

PowerPacTM HC High-Current Power Supply

公司名称: Bio-Rad Laboratories
产品编号: PowerPacTM HC High-Current Power Supply
Bio-protocol()
Company-protocol()
Other protocol()

Determination of H+-ATPase Activity in Arabidopsis Guard Cell Protoplasts through H+-pumping Measurement and H+-ATPase Quantification
Author:
Date:
2017-12-20
[Abstract]  The opening of stomata in plants in response to blue light is driven by the plasma membrane H+-ATPase in guard cells. To evaluate the activation of the H+-ATPase in vivo, we can use H+-pumping by guard cells in response to blue light and fusicoccin. To do this, it is required to prepare a large amount of guard cell protoplasts and measure H+-pumping in the protoplasts. It is also necessary to determine the protein amount of H+-ATPase. In this protocol, we describe the procedures required for these preparations and measurements. [摘要]  响应蓝光的植物气孔的开放是由保卫细胞中的质膜H + -ATPase驱动的。 为了评价体内H + -ATP酶的激活,我们可以使用H + +保卫细胞对蓝光的响应,fusicoccin。 为此,需要制备大量的保卫细胞原生质体,并测量原生质体中的H + - 抽吸。 还需要确定H + -ATP酶的蛋白质量。 在这个协议中,我们描述了这些准备和测量所需的程序。

【背景】响应于蓝光的气孔的开放是由穿过保卫细胞质膜上的H +介导的膜超极化驱动的(Assmann等,1985; Shimazaki等人,1986),并且是由质膜H + -ATP酶引起的(Kinoshita和Shimazaki,1999)。 H + -ATP酶在膜上产生电化学梯度,并提供植物细胞中许多次级运输所需的能量。然而,测量体内H + -ATP酶活性并不容易。利用保卫细胞的蓝光敏感特性,我们的方法可以将体内H +泵送作为体内测量H + + 使用拟南芥保卫细胞原生质体的ATP酶活性(Ueno等人,2005)。与通过蛋白质印迹(Yamauchi等人,2016)的Hβ+ -ATPase定量一起,该方法允许比较Hβ+ -ATPase活性不同的条件或突变背景。

Flow Cytometric Analysis of HIV-1 Transcriptional Activity in Response to shRNA Knockdown in A2 and A72 J-Lat Cell Lines
Author:
Date:
2017-06-05
[Abstract]  The main obstacle to eradicating HIV-1 from patients is post-integration latency (Finzi et al., 1999). Antiretroviral treatments target only actively replicating virus, while latent infections that have low or no transcriptional activity remain untreated (Sedaghat et al., 2007). To eliminate viral reservoirs, one strategy focuses on reversing HIV-1 latency via ‘shock and kill’ (Deeks, 2012). The basis of this strategy is to overcome the molecular mechanisms of HIV-1 latency by therapeutically inducing viral gene and protein expression under antiretroviral therapy and to ... [摘要]  消除HIV-1患者的主要障碍是后整合延迟(Finzi等人,1999)。抗逆转录病毒治疗仅针对主动复制病毒,而具有低转录活性或无转录活性的潜伏感染仍未得到治疗(Sedaghat等人,2007)。为了消除病毒性水库,一项战略重点是通过“休克和杀死”来逆转HIV-1潜伏期(Deeks,2012)。该策略的基础是通过在抗逆转录病毒治疗下通过治疗性诱导病毒基因和蛋白质表达来克服HIV-1潜伏期的分子机制,并通过病毒的溶解性质或现在识别感染细胞的免疫系统引起选择性细胞死亡。最近,许多研究已经描述了药物抑制人类溴结构域蛋白质的溴结构域和末端(BET)家族的成员的治疗潜力(Filippakopoulos等人,2010; Dawson等人& / em>,2011; Delmore等人,2011),其包括BRD2,BRB3,BRD4和BRDT。小分子BET抑制剂,例如JQ1(Filippakopoulos et al。,2010; Delmore等人,2011),I-BET(Nicodeme等人< / ...

产品评论